Cargando…

Neoadjuvant Chemoradiotherapy for Stage III Non-Small Cell Lung Cancer

The local management of stage III non-small cell lung cancer is controversial. Although definitive chemoradiotherapy (CRT) is considered a standard-of-care in the curative management of the disease, inadequate local control outcomes have led to various treatment strategies that incorporate surgical...

Descripción completa

Detalles Bibliográficos
Autor principal:	Sher, David J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2017
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5722802/ https://www.ncbi.nlm.nih.gov/pubmed/29255697 http://dx.doi.org/10.3389/fonc.2017.00281

Ejemplares similares

Concurrent sintilimab with sequential chemoradiotherapy for unresectable, stage III non-small cell lung cancer: a retrospective study
por: Tang, Shi, et al.
Publicado: (2023)

An open, observational clinical study of neoadjuvant therapy in resectable stage III non-small cell lung cancer
por: Qi, Yuwen, et al.
Publicado: (2023)

Are patients with stage III non-small cell lung cancer treated with chemoradiotherapy at risk for cardiac events? Results from a retrospective cohort study
por: Degens, Juliette, et al.
Publicado: (2020)

Severe radiation-induced lymphopenia during concurrent chemoradiotherapy for stage III non-small cell lung cancer: external validation of two prediction models
por: van Rossum, Peter S. N., et al.
Publicado: (2023)

Radiation Dose Escalation in Stage III Non-Small-Cell Lung Cancer
por: Terakedis, Breanne, et al.
Publicado: (2011)

Case Report: Aumolertinib as Neoadjuvant Therapy for Patients With Unresectable Stage III Non-Small Cell Lung Cancer With Activated EGFR Mutation: Case Series
por: Feng, Shao, et al.
Publicado: (2022)

Consolidation Immunotherapy After Platinum-Based Chemoradiotherapy in Patients With Unresectable Stage III Non-Small Cell Lung Cancer—Cross-Sectional Study of Eligibility and Administration Rates
por: Eichkorn, Tanja, et al.
Publicado: (2020)

Concurrent chemoradiotherapy for elderly patients with stage III non-small cell lung cancer
por: Kang, Ki Mun, et al.
Publicado: (2012)

Rationale for concurrent chemoradiotherapy for patients with stage III non-small-cell lung cancer
por: Conibear, John
Publicado: (2020)

Neoadjuvant and Adjuvant Immunotherapy: Opening New Horizons for Patients With Early-Stage Non-small Cell Lung Cancer
por: Bai, Rilan, et al.
Publicado: (2020)

Robotic-assisted thoracic surgery following neoadjuvant chemoimmunotherapy in patients with stage III non-small cell lung cancer: A real-world prospective cohort study
por: Gao, Yang, et al.
Publicado: (2022)

Neoadjuvant Chemoradiotherapy vesus Chemotherapy alone Followed by Surgery for Resectable Stage III Non-Small-Cell Lung Cancer: a Meta-Analysis
por: Guo, Shan xian, et al.
Publicado: (2016)

A Phase I Study of Dasatinib with Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer
por: Khurshid, Humera, et al.
Publicado: (2012)

Neoadjuvant Programmed Cell Death Protein 1 Blockade Combined With Stereotactic Body Radiation Therapy for Stage III(N2) Non-Small Cell Lung Cancer: A Case Series
por: Wang, Zhen, et al.
Publicado: (2022)

Real-world risk of brain metastases in stage III non-small cell lung cancer in the era of PET and MRI staging
por: Alhusaini, Saud, et al.
Publicado: (2023)

Neoadjuvant chemoradiotherapy for resectable gastric cancer: A meta-analysis
por: Chen, Jiuzhou, et al.
Publicado: (2022)

Emerging Therapies for Stage III Non-Small Cell Lung Cancer: Stereotactic Body Radiation Therapy and Immunotherapy
por: Kumar, Sameera S., et al.
Publicado: (2017)

Dosimetric Feasibility of Dose Escalation Using SBRT Boost for Stage III Non-Small Cell Lung Cancer
por: Hepel, Jaroslaw T., et al.
Publicado: (2012)

Concurrent chemoradiotherapy with low dose weekly gemcitabine in stage III non-small cell lung cancer
por: Abacioglu, Ufuk, et al.
Publicado: (2005)

Surgical Outcomes After Neoadjuvant Chemoimmunotherapy for Resectable Non-Small Cell Lung Cancer
por: Hu, Yan, et al.
Publicado: (2021)

Role of Neoadjuvant Chemotherapy in Non-small Cell Lung Cancer in the COVID-19 Pandemic
por: Karaman, Elanur, et al.
Publicado: (2022)

Progress on neoadjuvant immunotherapy in resectable non-small cell lung cancer and potential biomarkers
por: Wu, Xinyu, et al.
Publicado: (2023)

Advances in efficacy prediction and monitoring of neoadjuvant immunotherapy for non-small cell lung cancer
por: Wang, Yunzhen, et al.
Publicado: (2023)

Neoadjuvant camrelizumab and chemotherapy in patients with resectable stage IIIA squamous non-small-cell lung cancer: Clinical experience of three cases
por: Li, Xin, et al.
Publicado: (2022)

Neoadjuvant Treatment for Resectable and Borderline Resectable Pancreatic Cancer: Chemotherapy or Chemoradiotherapy?
por: Versteijne, Eva, et al.
Publicado: (2022)

Surgical perspective in neoadjuvant chemoimmunotherapy for stage II–III non‐small cell lung cancer
por: Hong, Tao, et al.
Publicado: (2021)

Prediction and clinical impact of delayed lymphopenia after chemoradiotherapy in locally advanced non-small cell lung cancer
por: Kang, Byung-Hee, et al.
Publicado: (2022)

Case Report: Neoadjuvant and Adjuvant Crizotinib Targeted Therapy in Stage IIIA-N2 ALK-Positive Non-Small-Cell Lung Cancer
por: Xie, Xiao-Hong, et al.
Publicado: (2021)

Before or After: Evolving Neoadjuvant Approaches to Locally Advanced Non-Small Cell Lung Cancer
por: Lewis, Jennifer, et al.
Publicado: (2018)

Use of Pralsetinib as Neoadjuvant Therapy for Non-Small Cell Lung Cancer Patient With RET Rearrangement
por: Zhou, Ning, et al.
Publicado: (2022)

Real‐world outcomes of chemoradiotherapy for unresectable Stage III non‐small cell lung cancer: The SOLUTION study
por: Horinouchi, Hidehito, et al.
Publicado: (2020)

Early recurrence factors in patients with stage III non‐small cell lung cancer treated with concurrent chemoradiotherapy
por: Takahara, Yutaka, et al.
Publicado: (2022)

Neoadjuvant immunotherapy and neoadjuvant chemotherapy in resectable non-small cell lung cancer: A systematic review and single-arm meta-analysis
por: Wang, He, et al.
Publicado: (2022)

Phase 3 Randomized Low-Dose Paclitaxel Chemoradiotherapy Study for Locally Advanced Non-Small Cell Lung Cancer
por: Lin, Hongmei, et al.
Publicado: (2016)

Outcomes of “sandwich” chemoradiotherapy compared with chemotherapy alone for the adjuvant treatment of FIGO stage III endometrial cancer
por: Wang, Shao-Jing, et al.
Publicado: (2022)

Evaluation of Postoperative Radiotherapy Effect on Survival of Resected Stage III-N2 Non-small Cell Lung Cancer Patients
por: Gao, Fei, et al.
Publicado: (2020)

Identification of Prognostic Model Based on Immune-Related LncRNAs in Stage I-III Non-Small Cell Lung Cancer
por: Li, Qiaxuan, et al.
Publicado: (2021)

Real-world clinical practice and outcomes in treating stage III non-small cell lung cancer: KINDLE-Asia subset
por: Prabhash, Kumar, et al.
Publicado: (2023)

Neoadjuvant chemoradiotherapy is superior to chemotherapy alone in surgically treated stage III/N2 non-small-cell lung cancer: a retrospective single-center cohort study
por: Sinn, K., et al.
Publicado: (2022)

A Pilot Study (SWOG S0429) of Weekly Cetuximab and Chest Radiotherapy for Poor-Risk Stage III Non-Small Cell Lung Cancer
por: Chen, Yuhchyau, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_mf2404p0lqu3sno3v9h57f9kl4